Adaptive Biotechnologies Announces Preliminary Fourth Quarter and Full Year 2025 Results Adaptive Biotechnologies (Nasdaq: ADPT) reported preliminary, unaudited fourth quarter and full year 2025 results. Total revenue was approximately $72M in Q4 and $277M for FY2025, up 51% and 55% year‑over‑year. MRD revenue was about $62M in Q4 and $212M for the year, up 54% and 46% versus 2024; excluding an MRD regulatory milestone, MRD revenue grew 45% FY‑over‑FY. clonoSEQ tests delivered totaled ~30,000 in Q4 (+43%) and ~105,600 for the year (+39%). Cash and marketable securities were ~$227M at year end. Full audited results will be released during the February 2026 earnings call.

#ADPT Adaptive Biotechnologies Announces Preliminary Fourth Quarter and Full Year 2025 Results

www.stocktitan.net/news/ADPT/adaptive-biote...

#ADPT Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer

www.stocktitan.net/news/ADPT/adaptive-biote...

Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced growing interventional use of

#ADPT Adaptive Biotechnologies Showcases Leadership in Hematology-Oncology MRD with New clonoSEQ® Data Driving Treatment Interventions at 2025 ASH Annual Meeting

www.stocktitan.net/news/ADPT/adaptive-biote...

Here's my list of who could win...

1.) Biotechnology - train scientific foundation models for biology to automate drug/material discovery

Potential winners: #RXRX #DNA #SDGR #ABSI #TWST #ADPT

Adaptive Biotechnologies Reports Third Quarter 2025 Financial Results Adaptive Biotechnologies (Nasdaq: ADPT) reported third quarter 2025 results on November 5, 2025, showing strong MRD momentum and updated guidance.Key points: Q3 revenue $94.0M (includes $33.7M one-time Genentech amortization); excluding Genentech $60.2M (+40% YoY). MRD revenue $56.8M (+52% YoY) with clonoSEQ volume 27,111 (+38% YoY). MRD achieved cash flow positivity and an MRD Adjusted EBITDA of $7.0M. Company Adjusted EBITDA was $28.0M. Cash and marketable securities were $216.8M. Company raised full-year MRD guidance to $202–$207M and narrowed operating spend and cash burn guidance.

#ADPT Adaptive Biotechnologies Reports Third Quarter 2025 Financial Results

www.stocktitan.net/news/ADPT/adaptive-biote...

#TEM has skyrocketed. But that's more healthcare AI. Lotta biotech AI names remain depressed, and that may be a set-up for a big move higher in some of these stocks #RXRX #ADPT #SDGR #NNOX #TWST

Fresh highs, rising volume—ADPT just stepped into the spotlight. Is this the start of the next leg up?

#Trading #ADPT #SwingTrading

Fresh highs, rising volume—ADPT just stepped into the spotlight. Is this the start of the next leg up?

#Trading #ADPT #SwingTrading

Adaptive Biotechnologies Hits Major Milestone: MRD Business Turns Profitable with 42% Revenue Jump First-time profitability for MRD segment drives guidance raise. See how clonoSEQ test volume grew 37% and why management reduced cash burn targets. Get full details.

#ADPT Adaptive Biotechnologies Reports Second Quarter 2025 Financial Results

www.stocktitan.net/news/ADPT/adaptive-biote...

Adaptive Biotechnologies and Flatiron Health Announce Integration of clonoSEQ® MRD Testing into OncoEMR® Adaptive Biotechnologies (NASDAQ: ADPT) has announced a strategic integration of its clonoSEQ® test for measurable residual disease (MRD) assessment into Flatiron Health's OncoEMR® platform. The integration provides streamlined access to MRD testing for over 4,500 clinicians across 1,000 community-based cancer care locations in the United States.The integration, effective July 1, 2025, enables healthcare providers to order and review clonoSEQ MRD testing results directly within the Electronic Medical Record system. This development aims to improve testing workflows and provide real-time insights into patient disease status, particularly for blood cancer patients. The clonoSEQ test helps detect small numbers of cancer cells that may remain during and after treatment, serving as a key predictor of patient outcomes.

#ADPT Adaptive Biotechnologies and Flatiron Health Announce Integration of clonoSEQ® MRD Testing into OncoEMR®

www.stocktitan.net/news/ADPT/adaptive-biote...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Most searched small-cap stocks, Wed May 21st - #IQ #KULR #LEU #LGMK #NVTS #QMCO #QUBT #SPCE #VLRS #WINT #GPUS #EDBL #DAWN #CERS #CAAS #BTCS #BBAI #ALLO #AG #ADPT - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Adaptive Biotechnologies Reports First Quarter 2025 Financial Results Adaptive Biotechnologies (ADPT) reported strong Q1 2025 financial results with total revenue of $52.4 million, up 25% year-over-year. The company's MRD business, contributing 83% of revenue, grew 34% to $43.7 million, driven by a 36% increase in clonoSEQ test volume to 23,117 tests. Operating expenses decreased 9% to $82.0 million, and net loss improved to $29.8 million from $47.5 million in Q1 2024. The company raised its 2025 MRD revenue guidance to $180-190 million while reducing operating expense guidance to $335-345 million and cash burn target to $50-60 million. Cash position remained strong at $232.8 million as of March 31, 2025.

#ADPT Adaptive Biotechnologies Reports First Quarter 2025 Financial Results

www.stocktitan.net/news/ADPT/adaptive-biote...

Major Medicare Win: Adaptive's Cancer Test Gets 5-Year Coverage Extension New Medicare decision enables 5-year surveillance coverage for clonoSEQ in mantle cell lymphoma patients. Test priced at $2,007. See revenue implications.

#ADPT Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Surveillance in Mantle Cell Lymphoma

www.stocktitan.net/news/ADPT/adaptive-biote...

I FOUND these puppies I meant to sell a while ago lol

Taking $20 usd for each of them. If interested plz head over to my ko-fi where you can snag them!

#1 ko-fi.com/s/b36f87cdb2
#2 ko-fi.com/s/163d5beef3

#adoptable #furryart #desertruckus #forsale #adpt #commission

Plz share and boost 🙏♥️

Adaptive Biotech is a BU Y. #ADPT

Revolutionary 7x Sensitivity Boost: Adaptive's New Cancer Detection Test Transforms Lymphoma Monitoring Adaptive Biotechnologies advances DLBCL cancer monitoring with enhanced clonoSEQ assay, achieving 7x sensitivity. Medicare-covered test leads market with 2,800+ patients tested.

#ADPT Adaptive Biotechnologies Launches Assay Enhancements to Increase clonoSEQ® Sensitivity for Clinical MRD Detection in Diffuse Large B-Cell Lymphoma

www.stocktitan.net/news/ADPT/adaptive-biote...

NEWS: ( NASDAQ: #ADPT ) (ADPT) Investment Report

Adaptive's MRD Division Hits Record Growth: Medicare Boosts Test Rates 17% as Volume Soars ADPT reports Q4 revenue of $47.5M with MRD segment driving growth. clonoSEQ test volume reaches new high amid Medicare reimbursement increase.

#ADPT Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results

www.stocktitan.net/news/ADPT/adaptive-biote...

Adaptive Biotech Partners with NeoGenomics to Transform Blood Cancer Testing with clonoSEQ Strategic collaboration integrates Adaptive's FDA-cleared clonoSEQ test with NeoGenomics' diagnostic services, expanding access to important MRD monitoring for blood cancer patients.

#ADPT Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients

www.stocktitan.net/news/ADPT/adaptive-biote...

Just In: ( NASDAQ: #ADPT ) Adaptive Announces IVDR Certification for clonoSEQ in European Union

#StockMarket #News